← signals
2026-07-04·ASML·export restriction
lowdown

As of July 4, 2026, Manifold Markets consensus on multiple questions reveals significant geopolitical risk for ASML.

As of July 4, 2026, Manifold Markets consensus on multiple questions reveals significant geopolitical risk for ASML.

window 20devidence 11confidence score 91price ASML $1769.32

confidence score

Strong evidence: 1 independent source class support this read.

91
low confidence1 independent source classesmarketpasses publish gate
priced-in check

ASML has not made a large direction-matching 30-90 day move yet.

not priced in
as of 2026-07-027d n/a45d n/a90d +35%yahoo

signal brief

As of July 4, 2026, Manifold Markets consensus on multiple questions reveals significant geopolitical risk for ASML. Notably, the question 'Will the US force ASML to halt exports to China before 2029?' shows a 50.00% probability (source 8). This is a substantial level of uncertainty that could impact ASML's revenue from China, a key market. Additionally, the probability that China will invent a domestic EUV machine by 2030 is 56.45% (source 7), indicating potential long-term competition. While ASML's monopoly on EUV remains highly probable through 2026 (79.92%, source 3) and even 2027 (69.43%, source 5), the export restriction risk is high enough to warrant monitoring. The odds of the US cutting ASML off Cymer (a critical component supplier) before 2030 stand at 43.06% (source 1), adding supply-chain fragility. These prediction market signals, though based on aggregated bets rather than confirmed policy, suggest growing headwinds for ASML's China business and its near-term outlook.

What the sources said:

  • Source 8: 'Will the US force ASML to halt exports to China before 2029? YES=50.00%'
  • Source 7: 'Will China invent a domestic version of ASML’s EUV lithographic machine tool by January 1, 2030? YES=56.45%'
  • Source 1: 'Will the US cut ASML off Cymer before 2030? YES=43.06%'

source data used

spillover entities

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.